Drug intelligence / Profile preview

PBX-CT-02

Development stage: Preclinical
Lead developer: PinotBio
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration: Intravenous

Overview

PBX-CT-02 is an antibody-drug conjugate (ADC) targeting Nectin-4, under development by Pinotbio. It is being investigated primarily for the treatment of non-small cell lung cancer and solid tumors. The drug acts as a Nectin-4 modulator, though its precise mechanism of action has not been fully defined in public sources. As of March 2025, it remains in preclinical development with no orphan drug designation and is considered a new molecular entity[1][2].

Other names: CT P71

Targets

PVRL4 (Nectin cell adhesion molecule 4)

Beyond the preview

Go deeper on PBX-CT-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBX-CT-02.